Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy

Maria Stamelou^{1

2

3}

Affiliations

¹ Parkinson's Disease and Movement Disorders Department, HYGEIA Hospital, Athens, Greece.
² First Department of Neurology, Aiginiteion Hospital, National and Kapodistrian University of Athens, Athens, Greece.
³ Neurology Clinic, Philipps-University, Marburg, Germany.

Editorial

Maria Stamelou. Mov Disord. 2019 Aug.

. 2019 Aug;34(8):1087-1088.

doi: 10.1002/mds.27778.

Maria Stamelou^{1

2

3}

¹ Parkinson's Disease and Movement Disorders Department, HYGEIA Hospital, Athens, Greece.
² First Department of Neurology, Aiginiteion Hospital, National and Kapodistrian University of Athens, Athens, Greece.
³ Neurology Clinic, Philipps-University, Marburg, Germany.

No abstract available

Keywords: criteria; diagnosis; progressive supranuclear palsy; therapeutics.

Comment on

Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.
Ali F, Martin PR, Botha H, Ahlskog JE, Bower JH, Masumoto JY, Maraganore D, Hassan A, Eggers S, Boeve BF, Knopman DS, Drubach D, Petersen RC, Dunkley ED, van Gerpen J, Uitti R, Whitwell JL, Dickson DW, Josephs KA. Ali F, et al. Mov Disord. 2019 Aug;34(8):1144-1153. doi: 10.1002/mds.27619. Epub 2019 Feb 6. Mov Disord. 2019. PMID: 30726566 Free PMC article.

1. Giagkou N, Stamelou M. Emerging drugs for progressive supranuclear palsy. Expert Opin Emerg Drugs 2019; https://doi.org/10.1080/14728214.2019.160945.
1. Respondek G, Roeber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013;28:504-509.
1. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 2017;32:853-864.
1. Respondek G, Kurz C, Arzberger T, et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 2017;32:995-1005.
1. Whitwell JL, Höglinger GU, Antonini A, et al. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord 2017;32:955-971.